ASX:IMMPharmaceuticals, Biotechnology & Life SciencesBiotechnology
IMMUTEP ORD
$0.045
$0.350 (88.61%)
Day Range
$0.028 - $0.050
52 Week Range
$0.028 - $0.470
Volume
432.93M
Avg Volume (10D)
1.26M
Market Cap
$66.32M
Price Chart
Market Statistics
Open$0.030
Previous Close$0.395
Day High$0.050
Day Low$0.028
52 Week High$0.470
52 Week Low$0.028
Valuation
Market Cap66.32M
Shares Outstanding1.47B
Price to Book5.89
Trading Activity
Volume432.93M
Value Traded16.26M
Bid$0.044 × 1,617,585
Ask$0.046 × 383,182
Performance
1 Day0.00%
5 Day3.95%
13 Week6.76%
52 Week43.64%
YTD-4.82%
Technical Indicators
RSI (14)14.86
50-Day SMA$0.400
200-Day SMA$0.303
Latest News
Hot Topics
Weekly Wrap: Shares fall another 2.6% for the week as conflict worsens
ASX 200 slides 2.6% this week to 8,617 as Iran-Israel conflict lifts oil above $100; NST and SYR plunge, while EOS soars on a Middle East contract.
3 min read
Biotechnology
Immutep doses first patient in Phase II/III efti trial to treat metastatic breast cancer
Biotechnology company Immutep (ASX: IMM) has safely dosed the first patient at a European clinical site for its integrated Phase II/III AIPAC-003 trial to treat metastatic breast cancer. AIPAC-003 is evaluating the company’s soluble LAG-3 protein and first-in-class MHC Class II agonist known as eftilagimod alpha (efti) in combination with standard-of-care paclitaxel for the treatment […]
2 min read
